Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6425310 | 0.86 | HSD11B1 (0.38) | — | |
| SCHEMBL354106 | 0.75 | — | — | |
| SCHEMBL356249 | 0.75 | CYP2C9 (0.33) | CYP2C9 | |
| SCHEMBL4946873 | 0.73 | TP53 (0.38) | CYP2C9 | |
| SCHEMBL354346 | 0.72 | HSD11B1 (0.45) | CYP2C9 | |
| SCHEMBL353657 | 0.70 | — | — | |
| SCHEMBL3279708 | 0.69 | CYP2C9 (0.41) | CYP2C9 | |
| SCHEMBL1548216 | 0.69 | SLC22A2 (0.39) | CYP2C9 | |
| SCHEMBL23302263 | 0.65 | LMNA (0.34) | — | |
| SCHEMBL5263068 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3702393-B1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM INC (JP) | 2025-01-15 | — | — | EP | claimed |
| US-11084888-B2 | Production method for low inclusion rate polyrotaxane | ASM, Inc. (JP) | 2021-08-10 | — | — | US | claimed |
| US-20200339709-A1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM, Inc. (JP) | 2020-10-29 | — | — | US | claimed |
| EP-3702393-A1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM Inc. (JP) | 2020-09-02 | — | — | EP | claimed |
| EP-3702393-B1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM INC (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-11084888-B2 | Production method for low inclusion rate polyrotaxane | ASM, Inc. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-20200339709-A1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM, Inc. (JP) | 2020-10-29 | — | — | US | disclosed |
| EP-3702393-A1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM Inc. (JP) | 2020-09-02 | — | — | EP | disclosed |
| CN-110240607-A | Bis- adamantane -4,5- glyoxalidine dichloro cuprous salt of 1,3- and preparation method thereof | 南京理工大学 | 2019-09-17 | — | — | CN | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| CN-1665801-B | Anti tubercular drug: compositions and methods | DEPT OF HEALTH AND HUMAN SERVI | 2011-05-11 | — | — | CN | disclosed |
| CN-101636376-A | Antituberculous drugs: compositions and methods | SEQUELLA INC | 2010-01-27 | — | — | CN | disclosed |
| CN-1665801-A | Anti tubercular drug: compositions and methods | DEPT OF HEALTH AND HUMAN SERVI (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1513825-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Department of Health and Human Services (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | CYP2C9 3361/4885 |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | CYP2C9 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.